Skip to content

Survodutide

Also called BI 456906

Dual GLP-1/glucagon receptor agonist engineered for appetite suppression plus increased energy expenditure and hepatic benefit.

  • TypePeptide
  • FormInjectable
  • Researched forMetabolic & Fat Loss

Where to get Survodutide

Flawless Compounds
Injectable
Code CAMERON

21+ to enter. The only form sold. Research compound, not approved for human use.

Shop injectable at Flawless Compounds

The short version

  • Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
  • What the evidence isIn phase 3.
  • What to watchPersistent upper belly pain, especially after fatty meals.

How Survodutide works

Survodutide is a glucagon receptor and GLP-1 receptor dual agonist, and unlike the rest of this class it has a paper describing how the ratio was chosen.

What was measured instead, and it is unusually concrete. The two arms were each given their own in vivo readout. Area under the curve 54% versus vehicle for survodutide against 45% for semaglutide, so the GLP-1 arm is doing roughly what a selective GLP-1 does.

  • Injectable

On the goal map: Hepatic fat & fatty liver (Metabolic health & insulin sensitivity)

Research on Survodutide6 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Human clinical evidence

  • In phase 3. Boehringer Ingelheim's GLP-1/glucagon dual agonist. Phase 2 reported around 19% mean weight loss at 46 weeks, placing it near tirzepatide territory.

  • The more distinctive phase 2 result was in MASH (fatty liver disease), where it achieved histological improvement in a large majority of patients — a harder endpoint than weight, requiring biopsy.

Correlative data

  • Not marketed anywhere; there is no real-world record. Trial tolerability looks like the class.

How the mechanism reads

  • Agonizes both GLP-1 and glucagon receptors, which sounds contradictory — glucagon raises blood sugar. The rationale is that glucagon also increases energy expenditure and drives hepatic fat oxidation, and GLP-1's glucose control offsets the glycemic downside.

    Mechanistic
  • That is why the liver result is the interesting one: burning hepatic fat is a glucagon action specifically, not something a pure GLP-1 does. The dual design predicts exactly the effect the MASH data showed.

    Mechanistic
  • The predicted cost of adding glucagon is a higher heart rate and greater reliance on getting the receptor ratio right.

    Mechanistic

Sources

  • Zimmermann T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism 2022 · PMID 36356832
  • Thomas L, et al. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection. Diabetes, Obesity and Metabolism 2024 · PMID 38560764
  • Jungnik A, et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, Obesity and Metabolism 2023 · PMID 36527386
  • Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine 2024 · PMID 38847460
  • le Roux CW, et al. New England Journal of Medicine 2026 · PMID 42253238
  • Zimmermann T, et al. Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. Molecular Metabolism 2026 · PMID 41638399

Survodutide safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Medullary thyroid cancer, in you or a close relative, or MEN2: GLP-1 receptor agonists carry that rodent signal.
  • Pancreatitis or symptomatic gallstones: stronger appetite loss speeds stone formation.
  • Insulin or sulfonylurea treatment, since appetite loss and GLP-1 action both lower glucose.
  • Decompensated liver disease: the glucagon arm acts on hepatocytes and is untested in a failing liver.
  • Pregnancy or breastfeeding: dual incretin appetite suppression cuts the energy a pregnancy needs.

What’s expected

  • Appetite suppression, with the glucagon arm adding energy expenditure and liver fat reduction.
  • Nausea and reflux in the first weeks of any increase.
  • Slightly higher resting pulse.
  • Falling liver enzymes if you have fatty liver.

Watch for

  • Persistent upper belly pain, especially after fatty meals.
  • Yellow eyes, or dark urine with pale stools.
  • Palpitations at rest.
  • A neck lump or hoarse voice.

Labs that tell you it’s working

  • Comprehensive Metabolic Panel (CMP)
  • Lipase
  • Enhanced Liver Fibrosis (ELF) Test
  • HbA1c (Hemoglobin A1c)

Dual GLP-1 and glucagon agonist aimed at weight and fatty liver; pancreas, gallbladder and liver labs match its two arms. PMID 38847460 PMID 42253238

Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON

A panel picked from how it works and what it can move: the tests, and why each is on it.

9 tests in one order
Marek Diagnostics · no doctor’s visit
Code CAMERON
Order this panel

Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.

The “On a GLP-1 (Semaglutide / Tirzepatide)” panel, explained

Survodutide FAQ4 common questions

Is Survodutide approved for human use?
No. Survodutide is a research compound.
What is Survodutide researched for?
Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Which labs show whether it's doing anything?
Comprehensive Metabolic Panel; Lipase; Enhanced Liver Fibrosis; HbA1c: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Survodutide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Survodutide is. Skool covers how it is run.

Free on this page

What Survodutide is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Survodutide is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool